Autism genetic testing cost and insurance: what families actually pay

The honest range: what genetic testing for autism actually costs

There is no single price for “genetic testing.” MedlinePlus, the National Library of Medicine’s consumer genetics site, puts the overall range at “under $100 to more than $2,000,” depending on the nature and complexity of the test — a range that was current on its site when we read it in September 2026. A chromosomal microarray or a single fragile X test tends to sit toward the lower end. Whole exome sequencing, which reads the protein-coding parts of roughly 20,000 genes at once, tends to sit toward the higher end, simply because it is reading far more genes letter by letter in one pass. You can read more about that comparison on our genetic testing, explained page.

Three different numbers can apply to the exact same test, and this is why two families sometimes get very different bills:

• List price — the amount the lab publishes or bills before any insurance discount is applied.
• Negotiated rate — the lower amount an insurer has agreed to pay that specific lab, if the lab is in-network.
• What your family owes — set by your plan’s deductible, copay, and coinsurance, applied to whichever of the above numbers your claim lands on.

Some labs quote a self-pay price that is lower than the amount billed to insurance; you have to ask, because it is rarely published. GeneDx, one genetic testing lab, states on its site (read September 2026) that the cost of genetic testing “varies depending on the test ordered, insurance coverage, and individual circumstances,” and points families to a financial assistance program. A family that bills insurance and gets a partial denial can end up owing more than a family that asked for the self-pay price up front. Before any sample is sent, ask the ordering clinic and the lab two questions: what is the list price, and what is the self-pay price if we don’t use insurance at all?

What insurers ask for before they’ll pay

Insurers do not pay for a genetic test because a child is autistic. They pay when a clinician documents medical necessity — a specific reason this specific test is needed for this specific child, tied to a diagnosis code. Autism-related billing codes sit in the ICD-10-CM F84 range; our diagnostic codes page explains how those codes work and how they connect to insurance claims.

Many plans also require prior authorization — approval before the test is run, based on paperwork your clinician submits in advance. Testing sent to the lab before authorization is granted can leave your family owing the full bill even if the plan would otherwise have paid.

The guideline insurers most often point to for exome and genome sequencing is a 2021 clinical guideline from the American College of Medical Genetics and Genomics (ACMG). Reviewing the evidence for children with congenital anomalies, developmental delay, or intellectual disability, the guideline’s authors — Manickam and colleagues — concluded that exome or genome sequencing “has a higher diagnostic yield and may be more cost-effective when ordered early in the diagnostic evaluation,” and recommended it be considered a first- or second-tier test for that group of children. One limit matters for autistic children specifically: that guideline states that isolated autism, without intellectual disability or a congenital anomaly, is formally out of its scope. If your child has no other medical features, expect a plan to lean on that, and expect the medical-necessity letter to have to work harder.

To see what “medical necessity” looks like in practice, it helps to read an actual payer policy. EviCore, a lab-benefit management company used by several health plans to review genetic-testing requests, publishes its criteria for autism, intellectual disability, and developmental delay testing. That particular guideline covers single-gene tests and gene panels; EviCore reviews microarray, exome and genome sequencing under separate guidelines. It is still a fair window onto how a payer defines medical necessity, because the same building blocks recur. Its 2026 guideline requires, among other things, that the child have “a formal diagnosis of ASD/autism, intellectual disability, and/or developmental delay,” at least one additional clinical feature beyond that diagnosis, and that the result would either change the child’s medical management or is needed because “a particular treatment is being considered” that requires a genetic answer first. The same guideline states that broad, non-targeted “comprehensive” autism gene panels are considered experimental or unproven and are not covered, and that most genetic tests are treated as medically necessary only once per lifetime, with limited exceptions for major technical advances.

Which tests are usually covered first follows a fairly consistent pattern across plans: chromosomal microarray and fragile X testing are typically the first tier, because they have been standard for years and are relatively less expensive — see our chromosomal microarray and fragile X pages for what each one looks for. The American Academy of Pediatrics’ 2020 clinical report says families “should be offered genetic evaluation, including chromosomal microarray and fragile X testing” (Hyman 2020). Whole exome sequencing coverage has been expanding as more medical societies endorse it, particularly once an earlier test comes back without an answer, but it more often requires its own separate prior authorization and its own medical-necessity letter.

Medicaid and CHIP: coverage that varies by state

Medicaid genetic-testing coverage is not one national policy — it is a federal floor with a great deal of state and managed-care variation on top of it.

The federal floor comes from the EPSDT benefit (Early and Periodic Screening, Diagnostic, and Treatment), which applies to every Medicaid-enrolled child under 21. Medicaid.gov states plainly that “when a screening examination indicates the need for further evaluation of an individual’s health, diagnostic services must be provided,” and that states must furnish medically necessary services “to correct and ameliorate health conditions” that are found. That is the legal basis for arguing that a medically necessary genetic test should be covered for a Medicaid-enrolled child, even when a specific test is not named in the general statute.

What that looks like in practice varies by state. As one worked example, North Carolina’s Medicaid program — in its Clinical Coverage Policy No. 1S-4, last amended in April 2023 — covers whole exome sequencing for beneficiaries age 21 or younger when several conditions are met together: the child’s features are “suspicious for a genetic diagnosis,” the child meets one of three feature routes — the one most relevant to autistic children is having at least two features from a listed set, one of which is explicitly “neurological features including either significant intellectual disability, global developmental delay or autism” — and a certified geneticist or a provider with genetic counseling experience evaluates the child before and after the test, the result will be used to guide care, and prior approval is not required unless the request exceeds specific test-frequency limits set in the policy. That is one state’s rules, not a national standard — your own state’s Medicaid program or managed-care plan may set different criteria entirely, so ask your caseworker for your state’s genetic-testing policy by name, and ask specifically whether your managed-care plan (rather than the state program itself) has its own separate prior-authorization process.

CHIP programs are generally run by the same state agencies as Medicaid and tend to follow similar diagnostic-necessity logic, but CHIP rules are also state-specific — the honest answer is to ask your CHIP plan the same questions you would ask a Medicaid managed-care plan: is this test covered, does it need prior authorization, and what documentation does the clinician need to submit. One caveat: EPSDT is a Medicaid benefit. States that run CHIP as a separate program rather than as a Medicaid expansion are not bound by it, so ask your CHIP plan directly rather than assuming the same rule applies.

The medical-necessity letter: what it must contain

A well-built letter of medical necessity is the single document most likely to move a denial to an approval. Based on what payer policies like EviCore’s actually ask for, hand your clinician this checklist:

1. Your child’s formal diagnosis — autism spectrum disorder, plus any co-occurring diagnosis, with the ICD-10-CM code your clinic uses (see diagnostic codes).
2. The specific test being requested — chromosomal microarray, fragile X testing, exome sequencing, or genome sequencing, named exactly, not “genetic testing” in general.
3. At least one additional clinical feature beyond the autism diagnosis itself, if one is present — a family history, a period of developmental regression, a structural finding, or another feature the clinician has observed.
4. What was already tried or ruled out — for example, that a chromosomal microarray was already done and did not explain the picture.
5. Why the result would change care — a specific way the answer would change medical management, screening, or a treatment decision under consideration, not only “for information.”
6. Genetic counseling plans — many payer policies, including North Carolina’s Medicaid policy above, require counseling before and after the test; naming who will provide it can remove a reason for denial.

Ask the clinician to attach this letter to the actual evaluation report, not send it alone. A one-line note is easy to deny; a letter tied to a full report is not.

If you are denied: appeal steps

A denial is not the end of the process. In order:

1. Get the denial reason in writing. Ask specifically which requirement was not met — a missing code, a missing clinical feature, a missing counseling note, or a plan exclusion.
2. Ask for a peer-to-peer review. Many plans allow your ordering clinician to speak directly with the plan’s reviewing physician, which resolves some denials without a formal appeal.
3. File a formal internal appeal, attaching the full evaluation report and the letter of medical necessity, not only the original claim. Our diagnostic codes page has a sample appeal cover note you can adapt.
4. Request an external review if the internal appeal is denied. Most plans are required to offer an independent review outside the insurance company once internal appeals are exhausted; your denial letter should state how to request one.
5. If your child is on Medicaid, the route is different: appeal to the managed-care plan first, then request a state fair hearing. Your denial notice must tell you how, and the deadline is on that notice.

Calendar every deadline the day a denial letter arrives — appeal windows are set by your specific plan and stated in that letter, so read it for the exact date rather than assuming a standard number of days.

No-cost and lower-cost routes

If cost is the barrier, a few real options exist — each with limits worth knowing up front.

Research studies. SPARK, a national autism research study, is free to join — its FAQ states “There is no cost to join SPARK” and that enrollment “usually takes between 15 and 30 minutes” (read on its site in September 2026) — and includes an optional saliva sample for genetic analysis: SPARK’s site says you do not have to share DNA to take part, but the saliva sample is how a genetic result would come back. According to a SPARK article on its pilot results (published 2019, revised October 2022), roughly “one in ten families that enroll in SPARK get a genetic result,” based on analysis of its first 457 families, and families who do are contacted and offered that result through a genetic counselor. This is research, not a clinical diagnosis pathway — most participants will not get an individual result back, and a result found through research may still need clinical confirmation before a doctor acts on it.

Simons Searchlight is a related but different resource: a research registry for families who already have a genetic diagnosis. Its own site (read September 2026) describes it as a “natural history database, biorepository, and resource network,” and joining requires families to upload a genetic lab report — a report from testing they already had done elsewhere — and a genetic diagnosis on the list of conditions it currently studies. It is a good next step after a genetic cause is found, not a way to get an initial test.

Hospital financial assistance. Many children’s hospitals and academic medical centers run charity-care or financial-assistance programs for medically necessary services, including genetic testing ordered through their own genetics clinic. Nonprofit hospitals are required to have a written financial assistance policy and to tell you how to apply, so ask for it by name — “your financial assistance policy” — rather than asking whether one exists.

Lab patient-assistance programs. Some testing labs run their own assistance programs directly. GeneDx, for example, describes a financial assistance program on its site (read September 2026) with eligibility “determined based on household income, family size, and other qualifying factors,” open to applying “before testing, after submitting a sample, or after testing is complete and a bill has been issued.” Ask whichever lab your clinician plans to use whether it has a similar program, and ask before the sample ships, not after the bill arrives.

Ask for the self-pay price regardless. Even if you plan to bill insurance, ask the lab what its self-pay price would be. Occasionally the self-pay price is lower than what you would owe after a partial insurance denial.

If the bill already arrived. Both a lab’s financial-assistance program (GeneDx’s page says you can apply after a bill has been issued) and a hospital’s financial-assistance policy can still be applied for after the fact — ask before you pay it in full.

Questions to ask billing before the sample is sent

Ask the clinic’s billing office and the lab, in this order, before you consent to testing:

1. Is prior authorization required for this specific test, and has it been obtained yet?
2. What is the lab’s self-pay price if we choose not to bill insurance at all?
3. If insurance denies the claim, does the lab have a patient financial-assistance program we can apply to instead?
4. Which diagnosis code and test code will be submitted, so we can confirm our plan covers that exact combination?
5. Is genetic counseling required before or after the test under our plan, and who provides it?

Write down who you spoke to and the date. If a bill later contradicts what you were told, that record is what you hand to an appeal.

Does genetic testing actually save money? A short note on cost-effectiveness

Whether genetic testing is “worth it” financially is a fair question, and the honest answer depends on which test and which population.

A 2021 Israeli study by Tal-Ben Ishay and colleagues compared testing strategies for autistic children and found a chromosomal microarray alone was the most cost-effective strategy, with the combination of microarray plus exome sequencing close behind and exome sequencing alone the least cost-effective. Their model priced a microarray at about USD 1,170 per child and exome sequencing at about USD 2,270 per child, including counseling and parents’ time. That is one study, in Israel’s health system, and it should not be read as a claim about US insurance economics — but it is a sourced reminder that “more testing” and “more cost-effective” are not the same thing.

Separately, a 2019 multidisciplinary consensus statement led by Srivastava and colleagues reviewed the published evidence on exome sequencing across a broader group of children with neurodevelopmental disorders — global developmental delay, intellectual disability, and autism spectrum disorder combined — and found exome sequencing identified a cause in 36% of cases overall, compared with a previously reported 15–20% for chromosomal microarray in that broader group. The same paper frames the value of getting to an answer faster in blunt terms: avoiding what it calls the “diagnostic odyssey” — the numerous separate tests and appointments many families go through before any explanation is found. Every appointment and test in that odyssey has its own cost, in money and in time, even when no single one of them is expensive. A faster, better-targeted first test can mean fewer total tests billed over the following years, which is itself a form of cost control, even if the first test’s own price tag is higher.

The 2019 consensus statement actually argues for putting exome sequencing first; most payer policies and the Israeli cost analysis still start with the microarray. Both positions are live, and which one your plan follows is what decides your bill.

Some families weigh all of this and decide not to test. That is a legitimate decision, and nothing here is an argument that you should.

Questions parents ask after reading this

1. If our insurance denies the genetic test, does that mean genetics doesn’t think it’s needed?
2. Can we ask for a less expensive test first and add exome sequencing later if that one doesn’t find an answer?
3. Does it cost anything to enroll in a research study like SPARK, and can we still get clinical testing later if we do?
4. If we pay out of pocket now, can we submit the receipt for reimbursement once insurance approves it?

Bring these to your next call with billing or your insurer — a specific question gets a specific answer faster than a general one.

If you only do three things

1. Call your insurer’s member services line and ask, in writing if possible, whether genetic testing needs prior authorization and what code it will be billed under.
2. Ask your clinician for a letter of medical necessity before the sample is sent, using the checklist above.
3. Ask the lab directly for its self-pay price and financial-assistance program before you agree to bill insurance.

None of this guarantees approval. All of it improves your odds, and none of it costs you anything but a few phone calls.